Roche’s Subcutaneous Ocrevus Could Extend Access To Patients
A subcutaneous formulation of Roche’s best-selling drug will offer an alternative to a lengthy intravenous infusion. Both versions will be priced the same.
A subcutaneous formulation of Roche’s best-selling drug will offer an alternative to a lengthy intravenous infusion. Both versions will be priced the same.